I take 2 a day
Reginald-Opara, J
Affiliation: 1 Medical Oncology Department, Hospital Clnic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Institut dInvestigacions Biomdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain ORCID: Affiliation: 1 Medical Oncology Department, Hospital Clnic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Institut dInvestigacions Biomdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain 2 CIBEREHD, Network Centre for Hepatic and Digestive Diseases, National Spanish Health Institute Carlos III (ISCIII), 28029 Madrid, Spain 3 Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08036 Barcelona, Spain ORCID: Affiliation: 3 Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08036 Barcelona, Spain ORCID: Affiliation: 1 Medical Oncology Department, Hospital Clnic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Institut dInvestigacions Biomdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain Affiliation: 1 Medical Oncology Department, Hospital Clnic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Institut dInvestigacions Biomdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain Affiliation: 2 CIBEREHD, Network Centre for Hepatic and Digestive Diseases, National Spanish Health Institute Carlos III (ISCIII), 28029 Madrid, Spain 3 Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08036 Barcelona, Spain ORCID: Affiliation: 2 CIBEREHD, Network Centre for Hepatic and Digestive Diseases, National Spanish Health Institute Carlos III (ISCIII), 28029 Madrid, Spain 3 Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08036 Barcelona, Spain Email: [email protected] ORCID: Affiliation: 1 Medical Oncology Department, Hospital Clnic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Institut dInvestigacions Biomdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain 2 CIBEREHD, Network Centre for Hepatic and Digestive Diseases, National Spanish Health Institute Carlos III (ISCIII), 28029 Madrid, Spain Email: [email protected] ORCID: Explor Target Antitumor Ther
Samtidigt kan man notera att i det gonblick nyproduktion har slts s vergr det i befintligt bestnd
Precision targeting of PTMs remains challenging: Although specific phosphorylation sites and ubiquitination patterns are known to regulate NRF2 stability, developing modifiers that selectively target these modifications without affecting other pathways is technically demanding
